The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Seattle Genetics to Present at Upcoming Investor Conferences

Wednesday, September 05, 2012

Seattle Genetics to Present at Upcoming Investor Conferences09:00 EDT Wednesday, September 05, 2012 BOTHELL, Wash. (Business Wire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at three investor conferences in September. The presentations will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section. Morgan Stanley Global Healthcare Conference Tuesday, September 11, 2012 at 10:20 a.m. Eastern time (ET)   ThinkEquity 9th Annual Growth Conference Thursday, September 13, 2012 at 10:00 a.m. ET   UBS Global Life Sciences Conference Thursday, September 20, 2012 at 9:30 a.m. ET About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage antibody-drug conjugate (ADC) programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at www.seattlegenetics.com. Seattle Genetics, Inc.Peggy Pinkston, 425-527-4160ppinkston@seagen.com